Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients.
Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients.
复制标题
促红细胞生成素给药对血液透析患者血液和血浆粘度的影响。
DOI：
10.1097/00002480-198907000-00107
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
J. Hyatt
中科院分区：
文献类型：
--
作者：
N. Vaziri;C. Ritchie;P. Brown;J. Kaupke;K. Atkins;S. Barker;J. Hyatt
在6例贫血血液透析（HD）患者和5例同样贫血的安慰剂治疗的HD患者中研究了重组人促红细胞生成素（EPO）对全血和血浆粘度的影响。使用锥板粘度计测定透析前后的粘度。EPO治疗组的透析前红细胞压积和全血粘度值在12周内显着增加，但安慰剂治疗组则没有增加;两组的血浆粘度均没有变化。在第12周单次HD治疗前后测量的全血粘度显示显著升高。这一变化（以透析前值的百分比表示）在两组中相似。因此，在EPO治疗的患者中观察到的全血粘度的升高是红细胞浓度增加的结果，而不是EPO对血浆的影响的结果。此外，EPO似乎不改变HD对血液粘度的急性效应。
The effect of recombinant human erythropoietin (EPO) on whole blood and plasma viscosity was studied in six anemic hemodialysis (HD) patients, and five equally anemic placebo treated HD patients. Viscosity was determined pre- and postdialysis using cone-plate viscometry. Predialysis values for hematocrit and whole blood viscosity increased significantly over a 12 week period in the EPO but not the placebo treated group; plasma viscosity did not change in either group. Whole blood viscosity measured before and after a single HD session during week 12 revealed a significant rise. This change, expressed as a percent of the predialysis values, was similar in the two groups. Thus, the rise in whole blood viscosity seen in EPO treated patients is a result of the increase in erythrocyte concentration and not a result of an effect of EPO on plasma. In addition, EPO does not seem to alter the acute effect of HD on blood viscosity.